AURA BIOPHARM HAS RECEIVED A START-UP AND COMMERCIALIZATION GRANT FROM INNOVATION NORWAY
AURA Biopharm has received a start-up and commercialization grant of NOK 700.000 (≈ 74.000 €) to support activities to develop AUR-1001 for the treatment of APS.
Olav Flaten, CEO and Chairman of AURA Biopharm commented:
“AURA is very grateful for this generous grant. That will enable us to initiate important activities towards our set milestones. As AURA also was granted the maximum level of granting in this call, it illustrates that our project meets high international standards. This grant will increase the value of AURA Biopharm, as it is a first important step of soft funding. We are extremely happy for receiving this acceptance of quality from Innovation Norway, and for having this support from the Norwegian Government.”
Innovation Norway is the Norwegian Government’s most important instrument for innovation and development of Norwegian enterprises and industry, and supports companies in developing their competitive advantage and to enhance innovation.